PARP1 and breast carcinoma: In addition, the Poly(ADP-Ribose)-Polymerase 1 (PARP)-inhibitor olaparib and rucaparib, novel therapies, can be offered to patients with mCRPC if an inactivated Breast Cancer 1⁄2 gene is detectable [15,16].